Cancer Immunotherapy: Update Bulletin [March 2016]

Cancer Immunotherapy: Update Bulletin [March 2016]

Code: FW-21072016-14 | Published: Mar-2016 | Pages: 0 | FirstWord
Price :
$995.00
USD

* Required Fields

$995.00

Details

In this update, payers offer their views on the recent reform of the cancer drugs fund (CDF) and its impact on access to cancer immunotherapies in the UK. In light of the impressive data recently released for Juno Therapeutics’ lead CAR T-cell therapies for B-cell malignancies, payers express opinion about reimbursement and cost containment strategies for these drugs. Payers also react to the recently expanded approval of Keytruda for the first-line treatment of advanced melanoma, as well as Opdivo monotherapy and Opdivo plus Yervoy combination therapy for patients with unresectable or metastatic melanoma, regardless of BRAF mutation status

How do UK payers view the proposed changes to the Cancer Drugs Fund (CDF) approved by NHS England?
What opportunities does the reform present to companies developing cancer immunotherapies for the UK market?
From a UK payers’ perspective, what concerns does the CDF reform bring with it, especially in terms of NICE’s strategy?
Will the CDF reform allow improved access to cancer immunotherapies for the treatment of rarer cancers?
How will the CDF reform impact the Early Access to Medicines Scheme (EAMS) in the UK?
Given the promising results from early-stage trials of Juno Therapeutics’ lead CAR T-cell therapies, what expectations do payers hold in terms of their likely coverage?
What cost containment strategies do payers foresee for CAR T-cell therapies and will these differ based on indication?
How do payers view the expanded approval of Keytruda for the first-line treatment of unresectable or metastatic melanoma?
With multiple cancer immunotherapies now available for the same indications, who will be most influential in terms of patients’ access to drugs in the US – payers or physicians?
How do payers view the extended approval of Opdivo plus Yervoy, and Opdivo monotherapy, for patients with unresectable or metastatic melanoma, regardless of BRAF-mutation status?
What role will predictive biomarkers play in guiding access to Opdivo and Yervoy in combination and to Opdivo monotherapy?
What strategies do US payers envisage could be used to contain the cost of cancer immunotherapies in the future?

Table of Contents


Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

Browse similar reports by category:
Pharmaceuticals & Healthcare
FirstWord

Our Clients